Gibco Diploid Serum-Reduced Medium helps reduce risk, cost and the danger of adventitious agents

Now you can transition to a reduced-serum medium for human diploid cells without sacrificing cell growth or virus expression. Gibco diploid serum-reduced medium (SRM) is a combination of two media to support vaccine manufacture under serum-reduced or serum-free conditions with human diploid cells such as MRC-5, Wl-38, KMB17, 2BS, as well as chicken embryo fibroblasts (CEF).

When culturing human diploid cells such as MRC-5, WI38, and KMB17 cell growth may be accomplished with 1–2% serum. Additionally, CEFs may be cultured serum-free. Virus production can then be conducted under serum-free conditions without the addition of serum or albumin.

Diploid SRM offers many benefits that a serum-containing complete medium does not, including

• Titer comparable to a serum-containing process
• Reduce process exposure to serum
• Lower cost due to reduction or elimination of serum
• Reduced risk of interrupted supply
• A better-defined source of nutrition to the cells
• Available in dry format (DPM) with liquid supplement*